Swiss contract drug manufacturer PolyPeptide Group AG has reportedly drawn takeover interest from private equity firms, including EQT AB and KKR & Co.
- Advent has also been studying a possible acquisition of PolyPeptide, according to the report.
- Any buyout firm pursuing a take-private deal could consider collaborating with Swedish businessman Frederik Paulsen Jr., the company’s billionaire controlling shareholder, Bloomberg reported.
- PolyPeptide shares have risen nearly 20% this year, increasing the company’s market value to about 1 billion Swiss francs (around $1.3 billion).
- The report noted that discussions are ongoing, and there is no certainty they will result in a completed transaction.
- Private equity firms declined to comment, Bloomberg said, while a PolyPeptide spokesperson stated that the company remains focused on executing its strategic plan.
